Literature DB >> 31856144

Identification of Long Non-Coding RNA Expression Profiles and Co-Expression Genes in Thyroid Carcinoma Based on The Cancer Genome Atlas (TCGA) Database.

Yun Zhang1, Taobo Jin1, Haipeng Shen1, Junfeng Yan1, Ming Guan1, Xin Jin1.   

Abstract

BACKGROUND Thyroid carcinoma is a malignancy with high morbidity and mortality. Genetic alterations play pivot roles in the pathogenesis of thyroid carcinoma, where long noncoding RNA (lncRNA) have been identified to be crucial. This study sought to investigate the biological functions of lncRNA expression profiles in thyroid carcinoma. MATERIAL AND METHODS The lncRNAs expression profiles were acquired from The Cancer Genome Atlas (TCGA) database according to 510 thyroid cancer tissues and 58 normal thyroid tissues. By using R package edgeR, differentially expressed RNAs were obtained. Also, an overall survival model was established based on Cox regression and clinical data then testified by Kaplan-Meier plot, receiver operating characteristic (ROC)-curve and C-index analysis. We investigated the co-expressed genes with lncRNAs involved in the prognostic model, as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was conducted R package clusterProfile. RESULTS A total of 352 lncRNAs were identified as differentially expressed in thyroid carcinoma, and an overall survival model consisting of 8 signature lncRNAs was proposed (ROC=0.862, C-index=0.893, P<0.05), 3 of which (DOCK9-DT, FAM111A-DT, and LINC01736) represent co-expressed mRNAs. However, as an oncogene, only FAM111A-DT increased the prognostic risk in thyroid carcinoma. Furthermore, we found differential genes LINC01016, LHX1-DT, IGF2-AS, ND MIR1-1HG-AS1, significantly related to lymph node metastasis (P<0.05). CONCLUSIONS In this study, we clarified the differential lncRNA expression profiles which were related to the tumorigenesis and prognosis in thyroid carcinoma. Our results provide new rationale and understandings to the pathogenesis and regulatory mechanisms of thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31856144      PMCID: PMC6931392          DOI: 10.12659/MSM.917845

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Thyroid carcinoma is one of the most malignant tumors and it is postulated that morbidity and mortality by thyroid carcinoma in USA are increasing observed in 2019 [1]. Pathologically, papillary thyroid carcinoma (PTC) represents 80% of thyroid tumors which derived from parafollicular C-cells, where follicular-cell originated carcinomas are most common. Except for PTC, follicular thyroid carcinoma (FTC) (15%), poorly differentiated thyroid carcinoma (PDTC) (<2%) and anaplastic thyroid carcinoma (ATC) (<2%) have constituted follicular cell-derived thyroid carcinoma. FTC and PDTC have a decent prognosis, while ATC has high mortality a survival 3-month to 5-month survival rate after first diagnosis [2,3]. Over the past few decades, the increased incidence of thyroid carcinoma is not only attributed to environmental changes, but also mainly attributed to improvements in early diagnosis of thyroid carcinoma [4-6]. Although thyroid carcinoma is a multifactorial disease (as many studies have shown), pathogenesis, including genetic alternations, plays vital roles in carcinogenesis. The phosphatidylinositol-3-kinase PI3K/AKT and mitogen-activated protein kinase (MAPK) has been extensively revealed alternations in thyroid carcinoma with different molecular mechanisms [7-9]. With the development of high-throughput sequencing technologies, more than 20 000 lncRNAs have been drawn attentions since these noncoding transcripts were regarding as gene trash elements before [10]. It is widely recognized that lncRNAs are participated in the regulation of transcription, splicing, translation, and imprinting [11-15]. Increasing studies of lncRNAs show that they play vital roles in various human disease, especially in cancer [16,17], where lncRNAs may exhibit as tumorigenic or tumor suppresser genes. Ding et al. demonstrated that lncRNA TPTEP1 could inhibit hepatocellular carcinoma cell development and occurrence by controlling IL-6/STAT3 signaling [18]. Yu et al. suggested AFAP1-AS1 was an oncogenic gene and that the AFAP1-AS1/LSD1/HBP1 axis could be a new therapeutic target in non-small cell lung cancer [19]. Similarly, thousands of lncRNAs are involved in tumorigenesis in thyroid carcinoma, but the characterization of differential lncRNA expressions and functional profiles in thyroid carcinoma remain unclear. In our study, we sought to analyze the differentiated lncRNA profiles in thyroid carcinomas by extracting from The Cancer Genome Atlas (TCGA) database. Additionally, investigated the relationship between differentiated lncRNAs and overall survival rate on patients. Also, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional analyses were conducted to show the functional mRNAs. To this end, we demonstrated that the lymph node metastasis was associated lncRNAs. Taken together, our results provide new insights for tumorigenesis and lncRNA related pathogenesis in thyroid carcinoma.

Material and Methods

Datasets and differentially expressed lncRNAs

The transcriptome profiling data of 510 thyroid carcinoma samples and 58 normal thyroid samples were obtained from The Cancer Genome Atlas (TCGA) in January 2019. The lncRNA sequencing data and related clinical information were generated and we download them by utilizing The GDC Data Transfer Tool (). Our study abides by the TCGA publication guidelines (). By comparing thyroid carcinoma tissues to normal tissues and using R package edgeR in R software (version 3.4.1), differentially expressed lncRNAs were identified with thresholds |log2FoldChange| >2 as well as adjusted P value <0.05. The lncRNAs were annotated by ENSEMBL (htps://) and depicted using the pheatmap package in R program. Ethical consent was not required because all the data in this study were obtained from the TCGA database.

Cox regression and survival analysis

All differentially expressed lncRNAs were subjected to univariate Cox regression with P value cutoff <0.01. Then the significant lncRNAs which related to univariate Cox regression were subsequently analyzed in a multivariate Cox proportional hazards model. By following the results of the multivariate Cox model and median risk score point, a total of 251 patients were grouped into “High risk” and “Low risk” respectively, where the risk score formula was shown as following: Risk score=βgene 1× exprgene 1+ βgene 2× exprgene 2+: : : + βgene n× exprgene n [20]. Cox regression analysis and Kaplan-Meier survival analysis were performed by using R package “survival”. The receiver operating characteristic (ROC)-curve analysis and C-index analysis were conducted to evaluate the consequence of the risk system we established, which were performed by using R package survivalROC and BiocManager, respectively. The log-rank test was employed to evaluate the statistical differences in overall survival, and survival curves were depicted by Kaplan-Meier analysis, where P<0.05 was considered as statistically significant.

LncRNAs-proteins correlations

The correlations between differentially expressed lncRNAs and related mRNAs were determined by using package limma in R program. The minimum interaction absolute value was set at medium confidence 0.400 with P value cutoff <0.001. Based on the results, all correlated genes were submitted to functional enrichment analysis for further validation.

Functional analysis

In order to demonstrate the biological functions of the differential expressed lncRNAs which involved in our predictive model, functional enrichment analysis was performed by analysis of GO and KEGG pathway. By analyzing all the lncRNAs correlated genes, as indicated, we used clusterProfiler package in R software to determine the molecular function, biological process and cellular component for GO analysis and pathway analysis in KEGG. The histograms for GO and KEGG were acquired by the R package GOplot.

LncRNAs related to lymph nodes metastasis

A total of 352 differentially expressed lncRNAs, as indicated, were analyzed in relation to 230 nonlymph nodes metastasis (N0) patients and 225 lymph nodes metastasis (N1) with thresholds |log2FoldChange| >2 as well as adjusted P value <0.05. Moreover, these lncRNAs which link to lymph nodes metastasis were visualized using the pheatmap package in R program.

Results

Differentially expressed lncRNAs in thyroid carcinoma

A total of 352 lncRNAs were identified as differentially expressed in thyroid carcinoma (510 thyroid carcinoma samples versus 58 normal thyroid tissues) (Supplementary Table 1). Of these, 166 lncRNAs (47.2%) were considered to be downregulated while 186 lncRNAs (52.8%) were upregulated. By visualizing the lncRNAs expression profiles, we performed volcano plot and heatmap to depict the overall differences among each gene (Figure 1A, 1B).
Figure 1

Differentially expressed lncRNAs in thyroid carcinoma. (A) Volcano plots show the distribution of differentially expressed lncRNAs. Upregulated lncRNAs were represented by red dots while the downregulated lncRNAs were represented by green dots. (B) Heatmap volcano plots show the distribution of differentially expressed lncRNAs, Red color represent up-regulated lncRNAs while the green color represents downregulated lncRNAs. lncRNAs – long noncoding RNAs.

Cox regression and overall survival model

A total of 352 differentially expressed lncRNAs were determined with univariate Cox analysis, as shown in Table 1. We found 12 lncRNAs to be significantly related to overall survival with univariate Cox regression at a significant level of P<0.01. Subsequently, we then performed a multivariate Cox regression analysis where a total 8 lncRNAs were found to be as coupled to a prognosis model for overall survival (P=5.2405e-06), of which DOCK9-DT, LINC00900, C8orf34-AS1, LINC01736 were suggested as protective factors while ATP2C2-AS1, FAM111A-DT, LINC02550, LINC01896 increased the risk in thyroid carcinoma (Figure 2). However, ATP2C2-AS1 and LINC02550 were downregulated genes, where the other 6 genes determine the opposite functions (Table 2). According to the overall survival model, we grouped patients into “high risk” and “low risk” groups, where the high-risk patients showed worse overall survival to low-risk group (P=1.0627e-04) (Figure 3A).
Table 1

Significant lncRNAs in univariate Cox regression (P<0.01).

GeneHRzP-value
LINC009000.578188577−3.2320092090.001229231
LINC024710.799698308−3.181172590.001466802
LINC025501.5874580963.1098037360.001872117
DOCK9-DT0.507389188−3.0218759710.002512135
LINC025550.814930817−2.8880492730.003876391
ATP2C2-AS11.9292193282.8415302130.00448976
LINC018961.3171078392.7677407380.005644634
FAM111A-DT0.510951459−2.7083955380.006760939
PAX8-AS12.0279294792.6207600060.0087734
C8orf34-AS10.660496757−2.6012711030.009287902
LINC019291.5499794622.5995848780.009333659
LINC017360.631751329−2.5806973170.009860099
Figure 2

Eight lncRNA expression profiles for prediction of overall survival in thyroid carcinoma by multivariate Cox regression. lncRNA – long noncoding RNA.

Table 2

Differentially expressed lncRNAs in overall survival model.

DElncRNAsRegulationLog fold changeFDR
DOCK9-DTUpregulation1.9071358013.87E-38
LINC00900Upregulation1.1228864215.38E-18
C8orf34-AS1Upregulation1.4313874424.08E-08
LINC01736Upregulation1.0019498640.000258681
ATP2C2-AS1Downregulation−1.3828543764.18E-24
FAM111A-DTUpregulation1.3173342355.38E-24
LINC02550Downregulation−1.0122453361.46E-05
LINC01896Upregulation2.6924332650.006280554
Figure 3

Cox regression and overall survival model. (A) Kaplan Meier plot showed significance between high-risk and low-risk patients in overall survival by the prognostic model (P<0.05). (B) The ROC curve analysis for the overall survival model (AUC=0.862) (C) The heatmap of 8 lncRNA expression profiles for prediction of overall survival model. ROC – receiver operating characteristics; AUC – area under the ROC; lnRNA – long noncoding RNA.

Additionally, ROC-curve analysis depicted the discriminative value of our established risk scoring system, where we found an AUC=0.862 (Figure 3B). Our risk scoring system was found to be highly sensitivity and specificity (100% and 94%) respectively in predicting overall survival, and the high-risk scoring group could be used for an impressive method for overall survival prediction. The heatmap represents the expression profiles of overall survival model based on the risk scoring system (Figure 3C). Also, we calculated the C-index value of our overall survival model, which is well proven (Table 3). Furthermore, the risk scores and survival status of all patients were visualized in Figure 4A and 4B where high-risk patients were significantly correlated to death as expected. Only 1 patient dead in the low-risk group (0.4%), while 15 patients dead in high-risk group (6.0%). Together, these data demonstrated that the impressive overall survival model based on the Cox regression could be a decent method for prognosis prediction.
Table 3

C-index value of the overall survival model.

C-indexSELowerUpperP-value
0.89260660.042604840.80910260.97611053.110781e-20
Figure 4

(A) Scatter diagram showed risk scores of thyroid carcinoma patients based on TCGA database. (B) Scatter diagram showed survivals statues of thyroid carcinoma patients based on TCGA database. TCGA – The Cancer Genome Atlas.

LncRNAs correlated mRNAs and functional analysis

A total of 3 lncRNAs (DOCK9-DT, FAM111A-DT, and LINC01736) were involved in the overall survival model and were found to be correlated to mRNAs expressions which co-expressed with 3274, 3412, and 31 mRNAs respectively. Based on the predicted Pearson correlation score, the top 5 correlating mRNAs of DOCK9-DT, FAM111A-DT, and LINC01736 are presented in Figure 5. We found a significantly strong correlation between DOCK9-DT and SDC4 (Cor=0.826, P=6.156e-143) and between FAM111A and FAM111A-DT (Cor=0.839, P=2.212e-151).
Figure 5

The correlation plots between differentially expressed lncRNAs and mRNAs. (A) The correlation plots of the top 5 correlated mRNAs of DOCK-DT. (B) The correlation plots of the top 5 correlated mRNAs of FAM111A-DT. (C) The correlation plots of the top 5 correlated mRNAs of LINC01736. lncRNAs – long noncoding RNAs, mRNA – messenger RNA.

To further investigate the biological functions of these co-expressed mRNAs, we conducted GO and KEGG functional analysis. As shown in Figure 6A, the results indicated that for GO analysis, most of the mRNAs were assembled in cell adhesion molecule binding with the lowest P-value at 8.33e-05 in FAM111A-DT while oxidoreductase activity, acting on the aldehyde or oxo group of donors represented the lowest P-value 6.82e-05 in DOCK9-DT. In addition, a total of 4 mRNAs were related to phospholipid binding in LINC01736. By analyzing the results of KEGG enrichment pathways, we found that in DOCK9-DT, a total of 70 genes were gathering in MAPK signaling pathway, while human papillomavirus infection reflects the most significant pathway including 85 genes in FAM111A-DT and Staphylococcus aureus infection represents the highest cancer associated pathway in LINC01736 (Figure 6B). These results indicated that these 3 lncRNAs might play vital roles in the tumorigenesis by targeting functional mRNAs.
Figure 6

Functional enrichment analysis for DOCK-DT, FAM111A-DT, and LINC01736 co-expressed genes. (A) Top 10 biological processes of GO analysis. (B) Top 10 pathways of KEGG enrichment analysis. GO – Gene Ontology; KEGG – Kyoto Encyclopedia of Genes and Genomes.

Lymph nodes metastasis-related lncRNAs

Since lymph nodes metastasis is a critical predictive factor in thyroid carcinoma [21,22], we further analyzed the relationship between differentially expressed lncRNAs and lymph nodes metastasis. Among 352 differentially expressed lncRNAs, we found that 4 upregulated genes (LINC01016, LHX1-DT, IGF2-AS, and MIR1-1HG-AS1) were significantly expressed across patients with N1 than N0 (Table 4), and the results were visualized by heatmap (Figure 7).
Table 4

Differentially expressed LncRNAs related to lymph node metastasis.

DElncRNAsRegulationLog fold changeFDR
LINC01016Upregulation3.8651463931.06E-28
LHX1-DTUpregulation5.2432756836.43E-28
IGF2-ASUpregulation5.0858261298.86E-38
MIR1-1HG-AS1Upregulation4.0191366888.86E-38
Figure 7

A heatmap of differentially expressed lncRNAs associated with lymph node metastasis. lncRNAs – long noncoding RNAs.

Discussion

The screening of RNAs transcripts was facilitated in the past 20 years and lncRNAs were testified to be an emerging factor which strongly associated with tumorigenesis and metastasis in thyroid carcinoma [23-26]. To understand the mechanism of genetic and epigenetic alterations in thyroid carcinoma, we investigated the transcriptomes files of thyroid carcinoma and normal thyroid samples based on TCGA database. We clarified that some lncRNAs have significantly interactions with overall survival, and the predictive survival model was established where some gene expression signatures were well elucidated. Furthermore, LINC01016, LHX1-DT, IGF2-AS, and MIR1-1HG-AS1 showed the possibility related to lymph node metastasis in the thyroid. We found in our overall survival prediction survival model that DOCK9-DT, LINC00900, C8of34-AS1, and LINC01736 exerted as protective factors in prognosis, while ATP2C2-AS1, FAM111A-DT, LINC02550, and LINC01896 increased the risks; however, only FAM111A-DT and LINC02550 exerted as oncogenes in thyroid carcinoma as well as significantly positively correlated with poor outcomes in patients. Interestingly, these lncRNAs have not been reported or studied before, the prognostic value of these bundles of genes and our overall survival model remains to be confirmed and demonstrated. Previous results [27] suggested that FAM111A-DT could be the most promising genes in tumorigenesis of thyroid carcinoma, by numerous binding mRNAs with high correlation index. FAM111A-DT, which named as FAM111A divergent transcript, ubiquitously expressed in 25 tissues including thyroid gland. This study validated that there is a significant correlation between FAM111A-DT and FAM111A, which confirmed early findings [28] that new susceptibility loci reached on chromosomes 11q12 (FAM111A-FAM111B) were linked to the carcinogenesis of prostate cancer. Fernandez et al. indicated that FAM111A expression could predict the possibility of local advanced cervical cancer patients who are developing distal metastasis [29]. Our results showed for thyroid carcinoma were consistent with these previous studies, suggesting the relations of FAM111A with tumorigenesis and prognosis. Additionally, 3 (DCSTAMP, PTPRE, and SLC34A2) of top 5 correlated genes of FAM111A-DT were reported to be positively correlated with the development of thyroid carcinoma [30-33]. However, biologically, functional experiments and larger cohort studies should be performed in the future to further explain the molecular mechanisms of FAM111A-DT in thyroid carcinoma as it only showed a trend in the Cox proportional hazards model (P=0.052) It is well known that the clinicopathological features, such as distal tumor metastasis and lymph node metastasis, as well tumor grade or staging have been proven to be pivotal prognostic factors in thyroid carcinoma, but the relationship with lncRNAs expression profiles remains obscured. In our study, one of the novel and potentially important findings was that LINC01016, LHX1-DT, IGF2-AS, and MIR1-1HG-AS1 were significantly linked to tumorigenesis and lymph node metastasis. None of the lncRNAs have been investigated except IGF2-AS. It has been proposed that IGF2 encodes a member of the insulin family of polypeptide growth factors, which promote growth-promoting activity possess. Consequently, as an antisense RNA of IGF2, IGF2-AS plays an important role in various cancers, including neuroblastoma and prostate cancer [34,35]. However, the function of IGF2-AS in thyroid carcinoma has not been elucidated yet; larger cohort is needed to testify the role and mechanisms.

Conclusions

We have identified differentially expressed lncRNAs based on TCGA database which associated with oncogenesis and prognosis of thyroid carcinoma. Although many lncRNAs showed promising and novel roles as biomarkers, lack of literature support limits the determinacy of these gene signatures. Future mechanistic studies are needed to validate these finding using functional experiments in vivo and in vitro. Importantly, our study provides new understandings for future studies of lncRNAs in thyroid carcinoma. A list of 352 differentially expressed lncRNAs.
Supplementary Table 1.

A list of 352 differentially expressed lncRNAs.

LncRNAlogFClogCPMPValueFDR
ADD3-AS1−1.544462734−0.999103477.41E-642.41E-61
LINC019773.8435101610.4804011743.30E-629.70E-60
RUNDC3A-AS11.9529990312.8191150591.60E-573.27E-55
LINC024544.5889970220.897828491.61E-573.27E-55
LINC02580−2.495858713−2.2367977965.59E-571.09E-54
STK32A-AS13.0344631361.0658386021.13E-541.85E-52
ST7-AS1−1.4481210921.6399165383.98E-535.75E-51
LINC024715.3227397543.4090627354.33E-536.20E-51
GASAL1−1.59528068−1.0593627565.43E-516.43E-49
UNC5B-AS14.9730403290.1305805135.60E-516.59E-49
ATP2B1-AS1−1.3075287811.4222517383.19E-503.59E-48
LPP-AS2−1.3088201550.3674280074.66E-505.12E-48
LNCTAM34A1.6446470870.8839156221.87E-481.74E-46
LINC02432−2.1823668970.0039753722.50E-482.30E-46
SEPT7-AS1−1.2716642941.1668095745.28E-474.43E-45
LINC01354−2.298558579−0.7435448785.17E-463.95E-44
LRP4-AS14.203658018−0.0814685525.23E-443.24E-42
STARD13-AS−1.594861034−1.8534684729.54E-445.81E-42
LINC02158−1.762893598−2.4347751756.45E-433.65E-41
LINC025603.8466131991.2794116494.80E-412.34E-39
LYPLAL1-DT−1.420355734−2.281515191.36E-406.33E-39
HAGLROS3.855538988−0.4873046661.88E-408.69E-39
LINC025556.1865819114.086007878.26E-403.63E-38
DOCK9-DT1.9071358013.4156341078.85E-403.87E-38
TNRC6C-AS12.52202454.4608280077.03E-392.85E-37
LINC017703.0334840560.7767864689.92E-393.95E-37
LINC01539−2.546623831−0.7400402332.60E-381.01E-36
LINC01672−2.533325932−2.6589010684.37E-381.66E-36
LINC01220−1.429512524−1.2107427769.94E-383.65E-36
TDRKH-AS11.381885950.2084166711.17E-374.24E-36
LINC024085.1476204441.1931023884.21E-371.47E-35
LINC020824.770468911−0.6535726636.00E-372.06E-35
RARA-AS11.4431012382.553329641.83E-366.13E-35
NR2F1-AS12.8973113893.8544691794.54E-361.48E-34
OR2A1-AS1−1.2091759222.5586637148.10E-362.59E-34
LINC01135−1.36651710.4640573215.03E-351.52E-33
LINC005142.298637682−0.9572511797.57E-352.26E-33
LINC01725−1.164413145−0.300100551.32E-343.86E-33
LINC011703.882335006−1.257563061.35E-343.95E-33
MIR181A2HG1.950703262.0236250636.77E-341.87E-32
MIR34AHG1.622572953−2.5211915821.46E-333.94E-32
SMAD9-IT1−1.920493079−2.0937235651.58E-334.27E-32
LINC014603.604749946−1.9252169271.98E-335.28E-32
ARHGAP31-AS1−1.11772071−1.212692732.12E-335.63E-32
LIFR-AS1−1.4577623482.0183459533.78E-339.79E-32
LANCL1-AS1−1.258442476−2.0036897325.84E-331.49E-31
MIR22HG−1.3044860224.8828871338.82E-332.23E-31
SNHG26−1.299920087−1.0763571153.09E-327.51E-31
CASC2−1.0050916642.597116514.02E-329.64E-31
KCNJ2-AS11.85991282.2038007584.31E-321.03E-30
LNCNEF−3.203013222−1.2986609256.62E-321.55E-30
LINC02028−1.6803209370.2444176042.17E-314.87E-30
TPRG1-AS1−1.918207633−2.4488677152.38E-315.33E-30
MORC2-AS1−1.32573386−2.1891077064.21E-319.19E-30
CYP1B1-AS12.0474824480.8646618955.08E-311.10E-29
PAX8-AS1−1.2197265283.1015187791.62E-303.37E-29
LINC01140−1.425900765−0.6320675198.84E-301.74E-28
FOXD2-AS11.5783736440.5463587411.59E-293.09E-28
TBC1D8-AS1−1.360224540.3890795232.50E-294.75E-28
LINC005113.1200315641.7425404367.18E-291.32E-27
LINC01361−1.760659712−3.128045558.96E-291.63E-27
PCAT14−2.687359418−1.0365480141.20E-282.15E-27
WWC2-AS2−1.004596422−0.0013462542.02E-283.60E-27
ATP6V0E2-AS1−1.6685989952.0209209172.17E-283.85E-27
LINC00472−1.1156359591.3913873023.07E-285.35E-27
LINC002843.786361822−0.4255370555.14E-288.84E-27
CYP4A22-AS12.079699245−2.6038399086.87E-281.17E-26
LBX2-AS11.4632645571.7556836218.58E-281.45E-26
RPL34-AS1−1.203128176−1.4584327738.79E-281.48E-26
LINC015104.229541483−1.3197844433.05E-274.87E-26
SYNE1-AS1−1.966150668−2.9771940553.09E-274.93E-26
BLACAT11.2797418713.022311773.10E-274.93E-26
KCNMB2-AS13.030847157−2.7978874753.19E-275.06E-26
FAM170B-AS14.141213927−2.0953439575.85E-279.08E-26
LINC017473.363198671−1.2676114046.05E-279.36E-26
MPPED2-AS1−2.779933864−0.9821805176.64E-271.02E-25
SNRK-AS1−1.562113657−1.6285482261.10E-261.67E-25
DCST1-AS11.1262172740.2870182351.13E-261.72E-25
A2M-AS1−1.0797976660.1383155471.55E-262.33E-25
LINC011371.0855154112.724409272.30E-263.38E-25
LINC008912.471054911−0.4218414942.34E-263.45E-25
LINC014832.591772438−0.6075020625.15E-267.36E-25
ATP2C2-AS1−1.382854376−1.7497497783.12E-254.18E-24
LINC006072.5639864090.7663918563.68E-254.88E-24
FAM111A-DT1.3173342353.8553426824.07E-255.38E-24
KIZ-AS1−1.361427086−2.7700243495.53E-257.25E-24
HAGLR3.2348423052.6715912479.06E-251.17E-23
LINC00092−1.6189404951.7341895029.80E-251.26E-23
TMEM92-AS13.368339962−2.7006818731.56E-241.96E-23
LINC01136−1.632608982−3.0439541881.77E-242.20E-23
LINC01126−1.382875629−1.3458872542.16E-242.68E-23
LINC00926−1.8174513240.8485489422.66E-243.27E-23
LINC023452.808452122−0.7098691383.40E-244.14E-23
SNX29P2−1.774050433−3.0613714923.54E-244.31E-23
THRB-AS1−1.228115348−1.4175973463.61E-244.38E-23
WDR11-AS1−1.258406396−1.8796189964.62E-245.55E-23
LINC02308−2.449471097−2.991053616.72E-247.98E-23
LINC019182.321282876−1.165457491.16E-231.35E-22
LINC00612−1.559936503−2.0389292461.91E-232.18E-22
FAM230B3.782245505−2.3373292782.66E-233.00E-22
CDKN2B-AS12.328544511−1.370432684.54E-235.03E-22
DCTN1-AS12.320679064−1.881629925.69E-236.27E-22
NAMA−1.695862202−2.7855544539.82E-231.06E-21
MIR31HG2.7729606521.1889401051.63E-221.72E-21
LINC016143.956293322−1.0669528981.65E-221.74E-21
ELN-AS1−1.0736197110.5178151271.99E-222.07E-21
CLIP1-AS1−1.396886915−3.0970809892.02E-222.10E-21
LINC01659−2.151654666−3.1960712912.73E-222.82E-21
LINC023433.189374218−2.7260187153.24E-223.32E-21
LINC012672.401810281−2.7089065937.65E-227.67E-21
LINC00609−1.636688954−2.5153836657.98E-227.98E-21
DUXAP82.525692559−1.1511474769.78E-229.72E-21
IGFL2-AS13.834169818−2.4856378681.28E-211.26E-20
LINC00506−1.384523233−1.8175037451.55E-211.52E-20
EIPR1-IT1−1.434838641−0.6302332311.57E-211.54E-20
FLJ167793.9111305921.1406165153.60E-213.39E-20
LINC02532−1.534790709−1.3220112923.77E-213.55E-20
LINC01508−1.3005357810.9733633644.80E-214.49E-20
LINC01058−1.203926684−3.197926485.62E-215.22E-20
PLA2G4E-AS1−1.206501944−2.6605108786.48E-215.99E-20
TCERG1L-AS12.049627044−1.247422416.53E-216.03E-20
PARAL14.346540422−1.7732153121.68E-201.50E-19
FZD10-DT−1.2240938180.5814770121.85E-201.65E-19
UCKL1-AS1−1.165628262−1.4275908882.71E-202.39E-19
LINC008531.1812037340.7165766482.75E-202.42E-19
ADAMTSL4-AS1−1.145373158−1.3362000982.85E-202.51E-19
GAPLINC1.597181425−1.7127295122.99E-202.63E-19
LINC01975−2.599270665−2.3006785463.88E-203.37E-19
TBILA−1.2610480771.9180442451.05E-198.82E-19
LINC01550−1.2495602670.8393506211.69E-191.39E-18
WWTR1-AS1−1.0171255840.2239478472.38E-191.94E-18
LINC008872.4322958081.1357309542.46E-192.01E-18
LINC014261.898942986−0.0287984752.54E-192.06E-18
MID1IP1-AS1−1.121699853−1.7106092774.35E-193.47E-18
LINC01985−1.442639538−3.0091025315.77E-194.54E-18
TNFRSF10A-AS11.0684175680.1298056755.85E-194.61E-18
LINC01814−1.067329139−0.182968786.03E-194.74E-18
NCAM1-AS1−1.876475157−3.0201851196.43E-195.04E-18
LINC009001.1228864212.2059564676.88E-195.38E-18
PGM5-AS1−1.75993484−2.9563305357.04E-195.49E-18
LINC01836−1.45054792−0.7165535988.73E-196.74E-18
HAND2-AS1−1.800404947−1.053775411.49E-181.13E-17
FAM181A-AS1−1.666658115−1.3836504361.59E-181.20E-17
LINC025932.1789983732.7000364051.76E-181.33E-17
LEMD1-AS11.531899488−1.5398174081.95E-181.46E-17
LINC00167−1.278875217−2.9711242742.30E-181.71E-17
LINC004603.331082757−2.690093252.71E-182.00E-17
LINC017041.683732006−2.7339754954.26E-183.10E-17
SH3PXD2A-AS11.6288274−2.356256874.36E-183.17E-17
LINC00982−1.3390580093.3070596774.49E-183.26E-17
ZNF571-AS11.4717780931.4857438055.63E-184.06E-17
CATIP-AS2−1.455702841−2.1024568827.83E-185.57E-17
HCG2040054−1.071754441−3.0586941138.48E-186.01E-17
NADK2-AS1−1.267928642−2.3450778941.05E-177.37E-17
FAM182A−1.525124056−2.3876190151.65E-171.14E-16
HCG222.532702042.3270724271.82E-171.25E-16
LINC01237−1.00802835−0.9035720112.40E-171.64E-16
VAC14-AS12.016076996−1.4035218884.29E-172.87E-16
SOX9-AS1−1.3777692330.5221307325.26E-173.49E-16
TMEM108-AS14.047490713−1.9250552276.17E-174.07E-16
LINC024615.681571486−1.6397178468.87E-175.80E-16
LINC022573.694696068−2.8409927419.62E-176.27E-16
SFTA1P2.027026167−0.2496305861.05E-166.83E-16
LINC016151.805083366−1.8005140291.22E-167.86E-16
LINC009421.832226061−1.3475013782.06E-161.30E-15
SEPT4-AS1−1.108555124−2.1205399732.06E-161.30E-15
LINC018782.73742996−1.2828144143.20E-161.98E-15
NAV2-AS4−1.646324166−2.9584183214.34E-162.65E-15
LINC02397−2.191000823−2.048930464.52E-162.76E-15
LINC024582.316587621−2.4384858764.68E-162.85E-15
NPSR1-AS14.778075117−2.5347932945.71E-163.45E-15
PTCSC3−1.1772460014.5507259417.77E-164.62E-15
MYCNOS−1.407429743−2.4579469087.82E-164.65E-15
LINC026031.328056569−1.697129638.05E-164.78E-15
VWA8-AS1−1.015148852−2.948364869.69E-165.72E-15
MAL2-AS1−1.150928064−2.2434547179.82E-165.79E-15
LINC00652−1.277394523−1.438021521.06E-156.24E-15
LINC009733.102991921−1.5507543052.22E-151.27E-14
LINC011761.201637370.8207501862.27E-151.29E-14
LINC012043.258598913−1.9838677592.44E-151.39E-14
CD44-AS11.515316083−0.7309554153.10E-151.75E-14
LINC02427−1.204613362−1.9824518913.47E-151.94E-14
EPHA5-AS1−2.559138368−2.2636410613.73E-152.08E-14
LINC024072.775865459−2.3968620154.19E-152.33E-14
FAM167A-AS1−2.200036412−1.521678676.90E-153.77E-14
BANCR−1.332417606−1.8647604166.99E-153.82E-14
PURPL3.333287808−1.8583575547.51E-154.09E-14
ITPR1-DT−1.400224026−0.6929116577.90E-154.29E-14
ZNF30-AS1−1.050761875−2.4801485168.92E-154.82E-14
ACBD3-AS11.158294887−1.4147758449.43E-155.08E-14
ADGRD1-AS1−1.504919287−0.3364273911.17E-146.25E-14
LINC00487−1.600011056−2.7759683361.24E-146.63E-14
LINC012241.431342497−1.1632103021.34E-147.12E-14
LINC017112.790153991−2.2635465331.42E-147.52E-14
TM4SF1-AS12.700697832−0.6834598751.94E-141.02E-13
CASC151.3940247690.9056770612.32E-141.21E-13
GUSBP111.0128355141.1274265392.68E-141.39E-13
LINC025351.798338705−2.3850339263.04E-141.57E-13
LINC01303−1.140793874−2.3991115554.08E-142.08E-13
SNAP25-AS11.569949042−1.9790439614.81E-142.44E-13
HRAT5−1.019022797−2.1566566496.66E-143.34E-13
LINC01571−1.1995489252.3223422547.30E-143.65E-13
LINC026002.3379902990.4427961188.40E-144.18E-13
DGUOK-AS11.0407144750.9640248028.57E-144.25E-13
UBXN10-AS11.0170970111.0057796679.08E-144.50E-13
SPANXA2-OT11.300402877−2.2172047781.28E-136.28E-13
FMR1-AS1−1.067781104−2.9639042431.42E-136.94E-13
CFLAR-AS1−1.032373666−0.2965104951.58E-137.68E-13
HOXA11-AS4.166628873−2.3837915611.80E-138.67E-13
LINC01257−2.181395918−1.6915334971.84E-138.86E-13
ZBTB20-AS4−1.047497562−2.9891315491.92E-139.24E-13
LINC02185−1.023094413−2.8911391841.95E-139.38E-13
LINC019681.48094991−2.1034673491.96E-139.42E-13
LINC009411.625347914−1.3874379853.78E-131.78E-12
LINC0024811.495418772−0.1432669334.34E-132.03E-12
LINC021883.229751041−1.5279726095.12E-132.38E-12
SMIM2-AS11.1784049540.3228237825.69E-132.64E-12
LINC013561.190556663−1.8318402226.24E-132.88E-12
LINC02147−1.072111191−2.8706557957.62E-133.48E-12
LINC019781.951430208−2.9803615688.71E-133.96E-12
LINC021592.397099936−0.9338000731.14E-125.13E-12
LINC012681.090115087−1.3037773241.17E-125.27E-12
BCRP31.1721404971.6943357481.23E-125.51E-12
CLDN10-AS14.005598887−2.9733814641.25E-125.62E-12
FENDRR−1.087861902−1.5112655661.71E-127.58E-12
LINC003652.180566649−2.1730468481.77E-127.85E-12
VLDLR-AS1−1.1916092010.6177647081.94E-128.57E-12
LINC01013−1.467488426−2.9218677662.09E-129.21E-12
CHRM3-AS2−1.729962854−1.3773694292.75E-121.20E-11
LINC023322.499668454−2.6436188032.87E-121.25E-11
EGOT1.549008427−0.5163296273.23E-121.40E-11
LINC011221.495796901−1.2255338613.50E-121.51E-11
WARS2-IT1−1.140761467−2.8924261073.84E-121.65E-11
MGAT3-AS11.921471241−3.1323154345.97E-122.52E-11
TMEM51-AS11.049425344−0.2786570466.93E-122.91E-11
DIO3OS−1.732138449−0.9355191247.98E-123.34E-11
HHIP-AS1−1.177273839−1.5747461348.47E-123.53E-11
PROX1-AS1−1.4925997840.1645820359.37E-123.89E-11
MIR222HG1.3478240694.1139663651.10E-114.52E-11
MKX-AS13.44096215−2.9628783311.12E-114.60E-11
TEX26-AS11.870701445−1.3045396181.91E-117.74E-11
C10orf911.347442868−1.3416939882.13E-118.58E-11
LINC01586−1.4879267870.5772299922.53E-111.01E-10
SRGAP3-AS4−1.09460423−3.0184584926.20E-112.40E-10
LINC01215−1.426380567−0.6115432097.13E-112.75E-10
MEG92.480937047−2.4170274627.48E-112.88E-10
LINC025161.681241882−2.6096076688.63E-113.30E-10
LINC019332.440700071−0.5754509931.08E-104.09E-10
LINC014511.738266137−3.0165327221.19E-104.49E-10
UCA13.111031028−1.6629347781.32E-104.94E-10
MIR646HG1.5872467210.8236254441.38E-105.18E-10
PACERR1.32108611−1.7396729211.71E-106.35E-10
PLAC4−1.179131972−3.1873216261.73E-106.41E-10
LINC00402−2.086388338−2.4239116621.79E-106.61E-10
LINC001131.878237395−2.203152451.85E-106.83E-10
PRR29-AS11.288952449−0.6443691912.18E-107.99E-10
NAV2-AS5−1.220830156−3.0448361022.38E-108.68E-10
LINC01781−2.191172737−2.2806385272.99E-101.08E-09
LINC013661.180959368−2.0871491684.83E-101.71E-09
LY6E-DT1.150565814−0.7449489284.93E-101.74E-09
LINC00877−1.32562314−1.545421775.02E-101.77E-09
TSIX−1.082612999−1.7506935925.69E-102.00E-09
MLIP-IT1−1.117952809−2.8590923716.15E-102.16E-09
LINC00861−1.2955892090.6763137366.51E-102.28E-09
FALEC2.187742734−1.3821643086.96E-102.43E-09
MYOSLID1.742193737−2.3936890528.97E-103.10E-09
LINC005781.499995698−1.3102382311.10E-093.78E-09
TCL6−1.947664766−1.8197819721.11E-093.80E-09
RNU6ATAC35P−1.075599348−2.2074385161.15E-093.94E-09
FGF13-AS1−1.228854208−1.5159726151.15E-093.95E-09
TMC3-AS1−1.011789762−1.0597256451.46E-094.93E-09
LINC017053.308082231−2.8217528021.66E-095.56E-09
LINC01502−2.098195941−1.4699818031.85E-096.17E-09
LINC002421.284297799−0.4397276081.91E-096.35E-09
LINC01857−1.517930886−1.4508059862.34E-097.73E-09
LINC020801.136512753−2.7141198063.34E-091.09E-08
LINC023472.51584231−3.1781095643.42E-091.11E-08
LINC02384−1.161842833−1.1063993424.33E-091.39E-08
LINC00892−1.30588597−1.8962093336.93E-092.18E-08
IL12A-AS11.56757292−2.1761502967.87E-092.46E-08
RNF157-AS1−1.0795086051.4767155929.97E-093.09E-08
LINC018431.297404227−3.0406324311.00E-083.10E-08
C8orf34-AS11.431387442−2.0315694661.34E-084.08E-08
LINC005741.305100436−1.7946082361.62E-084.92E-08
MIR205HG2.3506539080.5464881051.73E-085.21E-08
PGM5P3-AS1−1.066806842−3.1982341812.35E-086.99E-08
SMIM251.1421777041.4695202612.58E-087.65E-08
MIR4527HG2.188066145−2.9514485622.85E-088.39E-08
LINC019291.272249698−2.1258717133.08E-089.05E-08
DPP10-AS12.176483838−1.6551008773.13E-089.20E-08
LINC012932.967538508−1.7231919233.21E-089.42E-08
LINC021542.195301434−2.8046354253.76E-081.09E-07
KCCAT3331.89311652−2.1305869274.04E-081.17E-07
LINC01934−1.301524233−2.6542748764.18E-081.21E-07
LINC01133−1.486025422−2.7438010264.34E-081.26E-07
LINC01480−1.134594996−0.2523791284.91E-081.41E-07
LINC008363.169311285−3.1269674445.69E-081.63E-07
HPN-AS11.197442278−1.99463365.94E-081.69E-07
LINC009581.165391972.9565030576.23E-081.77E-07
EWSAT11.122167767−2.7251985897.62E-082.15E-07
C1QTNF1-AS11.078410505−3.03668877.78E-082.19E-07
LINC01115−1.318688616−2.7385469871.08E-072.99E-07
LINC00494−1.671536378−2.3272838881.10E-073.05E-07
LINC007072.297861456−2.9596202061.13E-073.11E-07
LAMP5-AS13.188247546−1.7420579551.27E-073.50E-07
PTPRD-AS1−1.0711848280.0336081761.34E-073.68E-07
PROSER2-AS1−1.0956404611.2605367712.01E-075.41E-07
FLJ128251.23632278−2.9302541112.54E-076.74E-07
GLIS3-AS11.732029993−0.4787941453.40E-078.90E-07
IGF2-AS3.625330184−0.9533500553.60E-079.41E-07
LINC008561.575984631−2.8704846233.79E-079.87E-07
RNF144A-AS11.321527479−2.2734053346.63E-071.69E-06
B3GALT5-AS1−1.2012773270.1689918777.45E-071.89E-06
LINC00944−1.071571769−2.9448725068.27E-072.08E-06
LINC02422−1.541154888−2.8835601131.49E-063.64E-06
LINC01281−1.430920089−2.5316657452.28E-065.45E-06
FAM83A-AS11.458937659−2.1146689142.77E-066.55E-06
LINC02273−1.082325192−1.8285674273.17E-067.45E-06
LINC025421.070062828−3.0324995473.81E-068.87E-06
NKAIN3-IT12.571006542−1.2944993156.12E-061.39E-05
LINC012351.1452751071.5312174736.17E-061.40E-05
LINC02550−1.012245336−1.5597294136.40E-061.46E-05
FAM30A−1.5321613391.3180108166.50E-061.48E-05
SLC12A5-AS11.037143804−2.4217940066.89E-061.56E-05
LINC00940−1.510161518−1.8542443359.61E-062.14E-05
LINC01885−1.353714064−1.0562761391.13E-052.50E-05
LINP11.238363304−2.3996276431.32E-052.88E-05
CERS3-AS11.521145283−3.2085622211.78E-053.84E-05
LINC010101.224418357−1.7063640891.91E-054.11E-05
MIR3945HG1.347395059−2.3827479892.19E-054.66E-05
LHX1-DT3.941038665−3.1648579672.32E-054.94E-05
LINC01976−1.235919046−2.6114559822.95E-056.21E-05
LINC015971.180394892−2.0385451666.32E-050.000128067
DLX6-AS11.026349641−1.5090820877.11E-050.000142994
LINC005251.174432004−2.7312947348.64E-050.000172065
LINC02576−1.187034556−2.1412129760.0001020110.000201612
IFNG-AS1−1.300736035−1.9723705040.0001023880.000202312
SLC26A4-AS1−1.0076530228.5543744740.0001086940.000213992
LINC017831.058124593−2.5879250420.0001189320.000232589
LINC017361.001949864−2.2383064810.0001330390.000258681
LINC025441.125663027−1.2529837390.0002051760.000389425
DGCR101.008940155−2.9062387510.0003239160.000598487
LINC010162.014036935−3.0328890620.0005273570.0009492
LINC02232−1.397984509−0.7462624650.000804030.001413368
LINC00261−1.065417538−1.6446360730.0012192670.002090539
MIR1-1HG-AS11.541132604−2.0427764750.0013294330.002268781
LINC018962.692433265−2.1857630540.003928240.006280554
LINC006481.296137264−2.1521580540.0044598720.007064917
LINC01014−1.014153989−3.0849120650.0045878550.007252895
ZFY-AS1−1.51394898−0.6148034540.0047052640.007420158
LINC025061.825073446−2.9483303710.005356150.008366998
  35 in total

1.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Authors:  Iñigo Landa; Tihana Ibrahimpasic; Laura Boucai; Rileen Sinha; Jeffrey A Knauf; Ronak H Shah; Snjezana Dogan; Julio C Ricarte-Filho; Gnana P Krishnamoorthy; Bin Xu; Nikolaus Schultz; Michael F Berger; Chris Sander; Barry S Taylor; Ronald Ghossein; Ian Ganly; James A Fagin
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

2.  Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2.

Authors:  Stephen R Plymate; Rupal S Bhatt; Steven P Balk
Journal:  Cancer Cell       Date:  2015-02-09       Impact factor: 31.743

3.  Current thyroid cancer trends in the United States.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

4.  A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition.

Authors:  Manuel Beltran; Isabel Puig; Cristina Peña; José Miguel García; Ana Belén Alvarez; Raúl Peña; Félix Bonilla; Antonio García de Herreros
Journal:  Genes Dev       Date:  2008-03-15       Impact factor: 11.361

Review 5.  Follicular cell-derived thyroid cancer.

Authors:  Henning Dralle; Andreas Machens; Johanna Basa; Vahab Fatourechi; Silvia Franceschi; Ian D Hay; Yuri E Nikiforov; Furio Pacini; Janice L Pasieka; Steven I Sherman
Journal:  Nat Rev Dis Primers       Date:  2015-12-10       Impact factor: 52.329

6.  A robust biomarker of differential correlations improves the diagnosis of cytologically indeterminate thyroid cancers.

Authors:  Hugo Gomez-Rueda; Rebeca Palacios-Corona; Hugo Gutiérrez-Hermosillo; Victor Trevino
Journal:  Int J Mol Med       Date:  2016-03-18       Impact factor: 4.101

7.  Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics.

Authors:  Linn Fagerberg; Björn M Hallström; Per Oksvold; Caroline Kampf; Dijana Djureinovic; Jacob Odeberg; Masato Habuka; Simin Tahmasebpoor; Angelika Danielsson; Karolina Edlund; Anna Asplund; Evelina Sjöstedt; Emma Lundberg; Cristina Al-Khalili Szigyarto; Marie Skogs; Jenny Ottosson Takanen; Holger Berling; Hanna Tegel; Jan Mulder; Peter Nilsson; Jochen M Schwenk; Cecilia Lindskog; Frida Danielsson; Adil Mardinoglu; Asa Sivertsson; Kalle von Feilitzen; Mattias Forsberg; Martin Zwahlen; IngMarie Olsson; Sanjay Navani; Mikael Huss; Jens Nielsen; Fredrik Ponten; Mathias Uhlén
Journal:  Mol Cell Proteomics       Date:  2013-12-05       Impact factor: 5.911

8.  Identification and characterization of the lncRNA signature associated with overall survival in patients with neuroblastoma.

Authors:  Srinivasulu Yerukala Sathipati; Divya Sahu; Hsuan-Cheng Huang; Yenching Lin; Shinn-Ying Ho
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

9.  LncBook: a curated knowledgebase of human long non-coding RNAs.

Authors:  Lina Ma; Jiabao Cao; Lin Liu; Qiang Du; Zhao Li; Dong Zou; Vladimir B Bajic; Zhang Zhang
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

10.  Identification of differentially expressed genes in papillary thyroid cancers.

Authors:  Ki-Young Lee; Song Mei Huang; Shengjin Li; Jin-Man Kim
Journal:  Yonsei Med J       Date:  2009-02-24       Impact factor: 2.759

View more
  15 in total

1.  Prioritization of Osteoporosis-Associated Genome-wide Association Study (GWAS) Single-Nucleotide Polymorphisms (SNPs) Using Epigenomics and Transcriptomics.

Authors:  Xiao Zhang; Hong-Wen Deng; Hui Shen; Melanie Ehrlich
Journal:  JBMR Plus       Date:  2021-03-19

2.  Upregulation of the Long Non-coding RNA LINC01480 Is Associated With Immune Infiltration in Coronary Artery Disease Based on an Immune-Related lncRNA-mRNA Co-expression Network.

Authors:  Ting Xiong; Botao Xiao; Yueheng Wu; Yunfeng Liu; Quhuan Li
Journal:  Front Cardiovasc Med       Date:  2022-04-26

3.  Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma-Do They Exist?

Authors:  Sylwia Szpak-Ulczok; Aleksandra Pfeifer; Dagmara Rusinek; Malgorzata Oczko-Wojciechowska; Malgorzata Kowalska; Tomasz Tyszkiewicz; Marta Cieslicka; Daria Handkiewicz-Junak; Krzysztof Fujarewicz; Dariusz Lange; Ewa Chmielik; Ewa Zembala-Nozynska; Sebastian Student; Agnieszka Kotecka-Blicharz; Aneta Kluczewska-Galka; Barbara Jarzab; Agnieszka Czarniecka; Michal Jarzab; Jolanta Krajewska
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

4.  Single-Cell Profiling of Coding and Noncoding Genes in Human Dopamine Neuron Differentiation.

Authors:  Fredrik Nilsson; Petter Storm; Edoardo Sozzi; David Hidalgo Gil; Marcella Birtele; Yogita Sharma; Malin Parmar; Alessandro Fiorenzano
Journal:  Cells       Date:  2021-01-12       Impact factor: 6.600

5.  Identification of Epithelial-Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma.

Authors:  Weimin Zhong; Fengling Zhang; Chaoqun Huang; Yao Lin; Jiyi Huang
Journal:  Front Oncol       Date:  2020-11-25       Impact factor: 6.244

6.  Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.

Authors:  Yue Li; Ruoyi Shen; Anqi Wang; Jian Zhao; Jieqi Zhou; Weijie Zhang; Ruochen Zhang; Jianjie Zhu; Zeyi Liu; Jian-An Huang
Journal:  Front Cell Dev Biol       Date:  2021-03-18

7.  Combined molecular and mathematical analysis of long noncoding RNAs expression in fine needle aspiration biopsies as novel tool for early diagnosis of thyroid cancer.

Authors:  A Pontecorvi; S Nanni; C Possieri; P Locantore; C Salis; L Bacci; A Aiello; G Fadda; C De Crea; M Raffaelli; R Bellantone; C Grassi; L Strigari; A Farsetti
Journal:  Endocrine       Date:  2020-10-08       Impact factor: 3.633

8.  Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma.

Authors:  Peipei Wang; Yueyun Chen; Yue Zheng; Yang Fu; Zhenyu Ding
Journal:  Dis Markers       Date:  2021-10-19       Impact factor: 3.434

9.  Long non-coding RNA LINC00607 silencing exerts antioncogenic effects on thyroid cancer through the CASP9 Promoter methylation.

Authors:  Lanzhen Li; Zhongcheng Gao; Lei Zhao; Peiyou Ren; Hongyan Shen
Journal:  J Cell Mol Med       Date:  2021-07-07       Impact factor: 5.310

10.  Identification of Potential lncRNAs and miRNAs as Diagnostic Biomarkers for Papillary Thyroid Carcinoma Based on Machine Learning.

Authors:  Fei Yang; Jie Zhang; Baokun Li; Zhijun Zhao; Yan Liu; Zhen Zhao; Shanghua Jing; Guiying Wang
Journal:  Int J Endocrinol       Date:  2021-07-21       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.